ABSTRACT
BACKGROUND: Residual venous congestion is a major contributor to readmission of patients with heart failure, and the venous excess ultrasound (VExUS) score is a potentially useful tool to evaluate systemic congestion. OBJECTIVES: To investigate the association between VExUS score before hospital discharge among patients with heart failure and the risk of readmission due to acute decompensated heart failure (ADHF) within 90 days after discharge. METHODS: This prospective cohort study enrolled adults with signs and symptoms of ADHF, left ventricular ejection fraction of 40% or below (heart failure with reduced ejection fraction), New York Heart Association functional class II to IV symptoms, and clinical evidence of venous congestion necessitating intravenous diuretics. Just prior to discharge, we conducted VExUS score evaluation. The primary outcome was a composite endpoint of readmission or emergency visits due to ADHF within 90 days following hospital discharge. Statistical significance was set at p < 0.05. RESULTS: The cohort comprised 49 individuals, 11 (22.4%) of whom experienced the primary outcome. At discharge, 34.7% of participants had VExUS score 2 or 3. Patients with VExUS 2 and 3 had a higher proportion of the primary outcome when compared with patients with VExUS of 0 (35.3% versus 9%, p = 0.044). CONCLUSIONS: A significant proportion of patients with heart failure with reduced ejection fraction admitted for ADHF presented clinical and ultrasound signs of residual congestion at discharge. Patients with VExUS score of 2 or 3 at the time of hospital discharge were found to be at higher risk of readmissions or emergency visits due to ADHF after 90 days.
FUNDAMENTO: A congestão venosa residual é um dos principais contribuintes para a readmissão de pacientes com insuficiência cardíaca, e o escore de ultrassonografia de excesso venoso (VExUS) é uma ferramenta potencialmente útil para avaliar a congestão sistêmica. OBJETIVOS: O objetivo do presente estudo foi investigar a associação entre o escore VExUS antes da alta hospitalar em pacientes com insuficiência cardíaca e o risco de readmissão por insuficiência cardíaca agudamente descompensada (ICAD) em até 90 dias após a alta. MÉTODOS: O presente estudo de coorte prospectivo envolveu adultos com sinais e sintomas de ICAD, fração de ejeção do ventrículo esquerdo de 40% ou menos (insuficiência cardíaca com fração de ejeção reduzida), sintomas de classe funcional II a IV da New York Heart Association e evidência clínica de congestão venosa necessitando de diuréticos intravenosos. Momentos antes da alta, realizamos avaliação do escore VExUS. O desfecho primário foi um desfecho composto de readmissão ou visitas de emergência devido à ICAD dentro de 90 dias após a alta hospitalar. A significância estatística foi estabelecida em p < 0,05. RESULTADOS: A coorte foi composta por 49 indivíduos, dos quais 11 (22,4%) apresentaram o desfecho primário. Na alta, 34,7% dos participantes tiveram escore VExUS de 2 ou 3. Os pacientes com VExUS de 2 e 3 tiveram maior proporção do desfecho primário quando comparados aos pacientes com VExUS de 0 (35,3% versus 9%, p = 0,044). CONCLUSÕES: Uma proporção significativa de pacientes com insuficiência cardíaca com fração de ejeção reduzida admitidos por ICAD apresentou sinais clínicos e ultrassonográficos de congestão residual na alta. Pacientes com escore VExUS de 2 ou 3 no momento da alta hospitalar apresentaram maior risco de readmissões ou visitas de emergência por ICAD após 90 dias.
Subject(s)
Heart Failure , Patient Discharge , Patient Readmission , Humans , Heart Failure/physiopathology , Heart Failure/diagnostic imaging , Patient Readmission/statistics & numerical data , Female , Male , Aged , Patient Discharge/statistics & numerical data , Middle Aged , Prospective Studies , Acute Disease , Stroke Volume/physiology , Time Factors , Risk Factors , Risk Assessment , Predictive Value of Tests , Severity of Illness Index , Reference Values , Aged, 80 and overABSTRACT
Resumo Fundamento A congestão venosa residual é um dos principais contribuintes para a readmissão de pacientes com insuficiência cardíaca, e o escore de ultrassonografia de excesso venoso (VExUS) é uma ferramenta potencialmente útil para avaliar a congestão sistêmica. Objetivos O objetivo do presente estudo foi investigar a associação entre o escore VExUS antes da alta hospitalar em pacientes com insuficiência cardíaca e o risco de readmissão por insuficiência cardíaca agudamente descompensada (ICAD) em até 90 dias após a alta. Métodos O presente estudo de coorte prospectivo envolveu adultos com sinais e sintomas de ICAD, fração de ejeção do ventrículo esquerdo de 40% ou menos (insuficiência cardíaca com fração de ejeção reduzida), sintomas de classe funcional II a IV da New York Heart Association e evidência clínica de congestão venosa necessitando de diuréticos intravenosos. Momentos antes da alta, realizamos avaliação do escore VExUS. O desfecho primário foi um desfecho composto de readmissão ou visitas de emergência devido à ICAD dentro de 90 dias após a alta hospitalar. A significância estatística foi estabelecida em p < 0,05. Resultados A coorte foi composta por 49 indivíduos, dos quais 11 (22,4%) apresentaram o desfecho primário. Na alta, 34,7% dos participantes tiveram escore VExUS de 2 ou 3. Os pacientes com VExUS de 2 e 3 tiveram maior proporção do desfecho primário quando comparados aos pacientes com VExUS de 0 (35,3% versus 9%, p = 0,044). Conclusões Uma proporção significativa de pacientes com insuficiência cardíaca com fração de ejeção reduzida admitidos por ICAD apresentou sinais clínicos e ultrassonográficos de congestão residual na alta. Pacientes com escore VExUS de 2 ou 3 no momento da alta hospitalar apresentaram maior risco de readmissões ou visitas de emergência por ICAD após 90 dias.
Abstract Background Residual venous congestion is a major contributor to readmission of patients with heart failure, and the venous excess ultrasound (VExUS) score is a potentially useful tool to evaluate systemic congestion. Objectives To investigate the association between VExUS score before hospital discharge among patients with heart failure and the risk of readmission due to acute decompensated heart failure (ADHF) within 90 days after discharge. Methods This prospective cohort study enrolled adults with signs and symptoms of ADHF, left ventricular ejection fraction of 40% or below (heart failure with reduced ejection fraction), New York Heart Association functional class II to IV symptoms, and clinical evidence of venous congestion necessitating intravenous diuretics. Just prior to discharge, we conducted VExUS score evaluation. The primary outcome was a composite endpoint of readmission or emergency visits due to ADHF within 90 days following hospital discharge. Statistical significance was set at p < 0.05. Results The cohort comprised 49 individuals, 11 (22.4%) of whom experienced the primary outcome. At discharge, 34.7% of participants had VExUS score 2 or 3. Patients with VExUS 2 and 3 had a higher proportion of the primary outcome when compared with patients with VExUS of 0 (35.3% versus 9%, p = 0.044). Conclusions A significant proportion of patients with heart failure with reduced ejection fraction admitted for ADHF presented clinical and ultrasound signs of residual congestion at discharge. Patients with VExUS score of 2 or 3 at the time of hospital discharge were found to be at higher risk of readmissions or emergency visits due to ADHF after 90 days.
ABSTRACT
Background: Serotonin is a mediator of pulmonary hypoxic vasoconstriction. Experimental studies have shown that serotonin-mediated pulmonary vasoconstriction can be inhibited by cyproheptadine. The aim of this study is to assess whether treatment with cyproheptadine compared to usual care increases ventilatory support-free days during the first 28 days in patients with coronavirus disease 2019 (COVID-19) requiring ventilatory support. Materials and methods: This randomized, single-center, open-label clinical trial included patients who were admitted to the intensive care unit (ICU) requiring ventilatory support due to COVID-19. Patients allocated to the intervention group received cyproheptadine for 10 days. The primary outcome was ventilator-free days during the first 28 days. Results: Nineteen patients were randomized to receive cyproheptadine and 21 to the control group. The number of ventilatory support-free days during the first 28 days was not different between the two groups (15.0; 95% CI, 0.0-24.0 days in the control group vs 7.0; 95% CI, 0.0-19.0 days in the intervention group; p = 0.284). Conclusion: In patients with COVID-19 and in need of ventilatory support, the use of cyproheptadine plus usual care, compared with usual care alone, did not increase the number of ventilatory support-free days in 28 days. How to cite this article: Boniatti MM, Nedel WL, Rihl MF, Schwarz P, Parolo E, Moretti MMS, et al. Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients with COVID-19: An Open-label, Randomized Clinical Trial. Indian J Crit Care Med 2023;27(7):517-521.
ABSTRACT
OBJECTIVES: Venous congestion is a potential cause of acute kidney injury (AKI) and venous excess ultrasound (VExUS) score is a potentially useful tool in this scenario. The aim of this study is to verify whether the VExUS score can serve as a guide to decongestion in patients with severe AKI and whether the modification of the score can be associated with an increase in the number of renal replacement therapy (RRT)-free days in 28 days. METHODS: This quasi-experimental study was conducted in patients admitted to the intensive care unit who developed severe AKI. The intervention was to suggest to the attending physician the use of diuretic in patients with VExUS >1. After 48 hours, a new VExUS assessment was performed. Primary outcome was RRT-free days at Day 28. RESULTS: Ninety patients were included. Patients with a VExUS score >1 (n = 36) at enrollment had a greater use of diuretics in the following 48 hours (75.0%, n = 27) than patients with a VExUS ≤1 (n = 54) at enrollment (38.9%, n = 21), P = .001. Patients who reduced the VExUS score had a significantly greater number of RRT-free days at Day 28 (28.0; 8.0-28.0) when compared with those who did not reduce (15.0; 3.0-27.5), P = .012. CONCLUSIONS: We found a higher diuretic use in patients with a higher VExUS score, and patients who reduced the VExUS in 48 hours had significantly more RRT-free days in 28 days.
ABSTRACT
Cutaneous manifestations are considered an infrequent presentation of coronavirus disease 2019 (COVID-19) and are mostly described in outpatient settings. Its onset during the course of the severe COVID-19 disease has been poorly described in severe cases. Studies focused on dermatological manifestations mostly described maculopapular or pernio-like lesions and less frequently vesicular or varicella-like eruption. We described the occurrence of a vesiculopapular eruption in three laboratory-confirmed COVID-19 patients associated with severe lung injury in whom the skin findings preceded viral reactivation and recrudescence of hypoxemia. The potential mechanisms for COVID-19-related cutaneous manifestations include immune hypersensitivity, cytokine-release syndrome, deposition of microthrombi, and vasculitis.
Subject(s)
COVID-19 , Exanthema , Exanthema/etiology , Humans , SARS-CoV-2 , SkinABSTRACT
SUMMARY Cutaneous manifestations are considered an infrequent presentation of coronavirus disease 2019 (COVID-19) and are mostly described in outpatient settings. Its onset during the course of the severe COVID-19 disease has been poorly described in severe cases. Studies focused on dermatological manifestations mostly described maculopapular or pernio-like lesions and less frequently vesicular or varicella-like eruption. We described the occurrence of a vesiculopapular eruption in three laboratory-confirmed COVID-19 patients associated with severe lung injury in whom the skin findings preceded viral reactivation and recrudescence of hypoxemia. The potential mechanisms for COVID-19-related cutaneous manifestations include immune hypersensitivity, cytokine-release syndrome, deposition of microthrombi, and vasculitis.
Subject(s)
Humans , Exanthema/etiology , COVID-19 , Skin , SARS-CoV-2ABSTRACT
Malignant otitis externa is an invasive infection of the external auditory canal and temporal bone with potentially life-threatening complications. Elderly patients with type 2 diabetes mellitus are the population most commonly affected by malignant otitis externa, but any type of immunosuppression predisposes to the disease. Prader-Willi syndrome is a genetic cause of obesity, often associated with insulin resistance and type 2 diabetes mellitus. This report describes a case of a 21-year-old male patient with Prader-Willi syndrome who had malignant otitis externa that progressed to sepsis during hospitalization. To the best of the authors' knowledge, this is the first description of malignant otitis externa in a young patient with Prader-Willi syndrome.
ABSTRACT
A 10-year-old female presented with a palpable mass occupying the entire abdomen. Computerized tomography scan showed a large expansive lesion measuring 22 cm × 20 cm × 13 cm. The mass was resected and the diagnosis of leiomyoma was made from immunehistochemical findings. Mesenteric leiomyoma is an uncommon tumor among gastrointestinal stromal tumors.
ABSTRACT
Dor torácica é uma queixa comum na emergência, representando 9-10% das emergências não relacionadas a trauma. Destes, a Síndrome Coronariana Aguda (SCA) conta com 13-23,6% dos casos de dor torácica. No entanto, 1,7-2,2% dos pacientes que tinham suspeita de SCA foram subsequentemente diagnosticados com Cardiomiopatia de Takotsubo. Relatamos o caso de uma paciente do sexo feminino, 78 anos, branca, sem patologias prévias, com queixa de dor torácica em sufocamento de forte intensidade associada à dispneia logo após discussão com vizinhos. A paciente foi submetida à investigação e se chegou ao diagnóstico de Cardiomiopatia de Takotsubo. A paciente foi tratada com sintomáticos e liberada em condições de alta após uma semana, não apresentando episódios de dor torácica durante a internação. A Cardiomiopatia de T akotsubo não é rara, mas sim, subdiagnosticada. Considerar a Cardiomiopatia de Takotsubo no diagnóstico diferencial especialmente em mulheres na pós-menopausa com síndrome coronariana aguda irá prevenir os perigos potenciais do tratamento com agentes trombolíticos (AU)
Chest pain is a common complaint in emergency care, representing 9-10% of non-trauma emergencies. Of these, Acute Coronary Syndrome (ACS) accounts for 13 to 23.6% of cases of chest pain. However, 1.7-2.2% of patients with suspected ACS were subsequently diagnosed with Takotsubo cardiomyopathy. Here we report the case of a white female patient, 78, without prior conditions, complaining of chest pain in suffocation of strong intensity associated with dyspnea after an argument with neighbors. After an investigation Takotsubo cardiomyopathy was diagnosed. The patient was treated symptomatically and discharged after a week, with no significant episodes of chest pain during hospitalization. Although Takotsubo cardiomyopathy is not rare, it is underdiagnosed. Considering Takotsubo cardiomyopathy in the differential diagnosis, especially in postmenopausal women with acute coronary syndrome, will prevent the potential dangers of treatment with thrombolytic agents (AU)